Contact Us

Send 

Search

 

Cholestatic hepatitis C after chemotherapy containing rituximab in diffuse large B cell lymphoma

Adriano M. Pellicelli, Cecilia D’Ambrosio, Maria L. Dessanti, Roberto Villani, Lucia Fondacaro, Lucia Miglioresi, Lucia R. Grillo, Arnaldo Andreoli

Abstract

Rituximab is a chimeric anti-CD20 monoclonal antibody that is a widely used for the treatment of B cells non-Hodgkin lymphoma. The use of chemotherapy regimens containing rituximab in HCV-positive patients with non-Hodgkin lymphoma has been associated with liver dysfunction, but no cases of cholestatic hepatitis C were described. To our knowledge, this is the first case of cholestatic hepatitis C in an HCV-positive patient with diffuse large B-cell lymphoma describes in the literature. We discuss the pathogenetic mechanisms underlying this severe form of hepatitis and describe its evolution after antiviral treatment.

Key words. HCV., NHL., Liver damage., HCVRNA., Immunosuppression.

Article Metrics

The Official Journal of the Mexican Association of Hepatology, the Latin-American Association for the Study of the Liver and the Canadian Association for the Study of the Liver

© 2018 Annals of Hepatology. All rights reserved Privacy Policy